Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.2% – Should You Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price fell 4.2% during trading on Friday . The company traded as low as $12.97 and last traded at $12.99. 395,575 shares traded hands during trading, a decline of 77% from the average session volume of 1,748,399 shares. The stock had previously closed at $13.56.

Wall Street Analyst Weigh In

A number of research firms have commented on NTLA. Barclays reduced their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Wedbush reissued a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Finally, Oppenheimer cut their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.94.

Intellia Therapeutics Stock Performance

The stock has a 50 day moving average price of $16.23 and a 200 day moving average price of $20.70. The company has a market cap of $1.28 billion, a P/E ratio of -2.33 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period in the prior year, the firm posted ($1.38) EPS. The firm’s quarterly revenue was down 24.1% on a year-over-year basis. As a group, equities research analysts predict that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NTLA. Blue Trust Inc. raised its position in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $41,000. Values First Advisors Inc. acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $54,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after buying an additional 472 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.